Levodopa is preferred over dopamine for treating Parkinson disease primarily because:

Explanation

## Why Levodopa, Not Dopamine? **Key Point:** Levodopa (L-DOPA) crosses the blood–brain barrier via the large neutral amino acid transporter type 1 (LAT-1 / System L), whereas dopamine cannot cross because it is too polar and lacks a suitable transporter. ### Pharmacokinetic Basis **High-Yield:** The blood–brain barrier is impermeable to dopamine due to: - High polarity (catechol group with two hydroxyl groups) - Lack of active transport mechanism for dopamine itself - Presence of efflux pumps (MAO, COMT) that degrade dopamine peripherally Levodopa, being a neutral amino acid, is recognized by LAT-1 and actively transported across the BBB into the CNS, where it is converted to dopamine by aromatic amino acid decarboxylase (AADC). ### Clinical Implications 1. **Combination with carbidopa or benserazide:** These are peripheral AADC inhibitors that cannot cross the BBB themselves. They prevent premature conversion of levodopa to dopamine in the periphery, reducing: - Nausea and vomiting - Cardiac arrhythmias - Systemic hypertension - Wastage of levodopa 2. **Dosing:** Levodopa is given at much lower doses (250–500 mg three times daily) compared to what would be needed if dopamine were used. **Mnemonic:** **BBB-LAT** = Blood–Brain Barrier needs LAT transporter (Levodopa gets in, dopamine doesn't). ### Comparison Table | Feature | Dopamine | Levodopa | |---------|----------|----------| | BBB penetration | No (polar, no transporter) | Yes (LAT-1 transporter) | | Peripheral metabolism | Rapid (COMT, MAO) | Slower (AADC requires cofactor) | | CNS availability | ~0% | ~5–10% (rest peripheral) | | Peripheral side effects | Severe (unopposed) | Minimal (with carbidopa) | | Clinical use in PD | Not used | Gold standard |